Drug Profile
Research programme: anticancer antibody drug conjugates - Advanced Proteome Therapeutics/University of Toronto
Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Advanced Proteome Therapeutics
- Developer Advanced Proteome Therapeutics; Toronto Recombinant Antibody Centre
- Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer